CDMO LGM Pharma has announced a $9m investment into its facilities in Rosenberg, Texas and Colorado Springs, Colorado.
In a statement released this morning, the company said that the investment was to "increase commercial capacity, expand R&D capabilities and support continued demand for US-based drug product manufacturing."
The investment follows on from the company's previously announced $6m expansion in Rosenberg in 2025.
The Texas facility enhancements include a $4m investment to expand commercial-scale manufacturing suites for suppositories to meet increasing customer and market demand, including growth in women's health products.
The upgrades also expand R&D capabilities to support formulation and scale-up for suppositories, solutions, suspensions and semi-solids. LGM said that the Rosenberg site would remain fully operational throughout construction, with the planned upgrades already underway.
In Colorado Springs, the company plans to invest $5m to expand its commercial manufacturing capacity for niche, high-value oral solid-dose (OSD) products, including orally disintegrating tablets (ODTs).
This facility has been the company's centre of excellence for OSD development, with the expansion scheduled for completion this year and designed to address the increasing demand for domestic manufacturing.
"These multi-site investments totalling $15 million reflect our continued commitment to strengthening pharmaceutical supply chains in the United States," said Prasad Raje, CEO of LGM Pharma.
"Today's pharma companies need partners that are both resilient and integrated across the full product lifecycle."
By reinforcing domestic drug product manufacturing at the downstream end of the supply chain, closer to end markets and leveraging our global API sourcing capabilities upstream, we create a balanced end-to-end model.
"This gives customers greater control and visibility as they move products from development to commercialisation."
Speaking exclusively to Manufacturing Chemist, Raje explained how the upgrades would differentiate LGM Pharma's suppository and ODT manufacturing capabilities from other US-based CDMOs.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.